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Purpose: We previously reported that insulin resistance, low high-density lipopro-
tein (HDL) cholesterol, and glycaemic exposure Index are independently associated 
with peripheral neuropathy in Korean patients with type 2 diabetes mellitus. We fol-
lowed the patients who participated in that study in 2006 for another 6 years to deter-
mine the relationship between insulin resistance and neuropathy. Materials and 
Methods: This study involved 48 of the original 86 Korean patients with type 2 dia-
betes mellitus who were referred to the Neurology clinic for the assessment of dia-
betic neuropathy from January 2006 to December 2006. These 48 patients received 
management for glycaemic control and prevention of diabetic complications in the 
outpatient clinic up to 2012. We reviewed blood test results and the nerve conduction 
study findings of these patients, taken over a 6-year period. Results: Low HDL cho-
lesterol and high triglycerides significantly influenced the development of diabetic 
neuropathy. Kitt value (1/insulin resistance) in the previous study affected the occur-
rence of neuropathy, despite adequate glycaemic control with HbA1c <7%. Insulin 
resistance affected the development of diabetic neuropathy after 6 years: insulin re-
sistance in 2006 showed a positive correlation with a change in sural sensory nerve 
action potential in 2012. Conclusion: Diabetic neuropathy can be affected by previ-
ous insulin resistance despite regular glycaemic control. Dyslipidaemia should be 
controlled in patients who show high insulin resistance because HDL cholesterol and 
triglycerides are strongly correlated with later development of diabetic neuropathy. 
Key Words:   Insulin resistance, type 2 diabetes mellitus, diabetic neuropathy, met-
abolic syndrome
INTRODUCTION
Insulin is a hormone that plays an essential role in the maintenance of homeostasis 
between glucose uptake and production.1 Insulin resistance is defined by a state of 
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ological examinations, conducted 6 years previously, for 
the screening of diabetic neuropathy.
MATERIALS AND METHODS
　　　
Patients
This study involved 48 of the original 86 Korean patients 
with type 2 diabetes mellitus who were referred from the dia-
betes mellitus clinic at Gangnam Severance Hospital, Seoul, 
Korea, to the neurology outpatient clinic for the assessment 
of diabetic neuropathy from January 2006 to December 
2006. These 48 patients received management for glycae-
mic control and prevention of diabetic complications in the 
outpatient clinic up to 2012 (Fig. 1). We reviewed blood 
test results and the nerve conduction study findings of these 
patients, taken over a 6-year period. Subjects included those 
with symptomatic neuropathy as well as asymptomatic pa-
tients who had been referred for screening purposes. The 
diagnosis was based on a previous history of diabetes melli-
tus or using the American Diabetes Association’s diagnostic 
guidelines.13 Exclusion criteria were as follows: type 1 dia-
betes mellitus, severe liver dysfunction (alanine aminotrans-
ferase or aspartate aminotransferase more than 2 times the 
upper limit of normal values), severe renal dysfunction (se-
rum creatinine >1.6 mg/dL), current smoker, uncontrolled 
hypertension, recent infection history, malignancy, loss of 
reduced reactivity to insulin in target tissues such as liver, 
muscle, and adipose tissue, and is known to be a major fac-
tor in various physiological dysfunctions such as metabolic 
syndrome (obesity, hyperlipidaemia, hypertension, and glu-
cose intolerance).1,2 Insulin resistance and metabolic syn-
drome are the most important risk factors for type 2 diabetes 
mellitus in Western populations. Korean patients with type 2 
diabetes mellitus show different clinical characteristics from 
those in the West because of racial characteristics, dietary 
habits, and lifestyle. In Korea, however, the number of pa-
tients with type 2 diabetes mellitus who have insulin resis-
tance associated with metabolic syndrome has increased.3 
We recently showed that insulin resistance is independently 
associated with peripheral neuropathy in Koreans with type 
2 diabetes mellitus regardless of blood glucose level.4 
Conventional electrophysiological studies are widely used 
for the objective diagnosis of diabetic neuropathy. The phys-
iological function of nerves can be evaluated quantitatively 
by nerve conduction study (NCS).5,6 NCS abnormalities oc-
cur early in the course of type 2 diabetes mellitus, and the 
pattern of progression of peripheral neuropathy shows de-
pendence on the length of the nerve fibers.7 NCS shows 
complicated abnormalities of sensory, motor, and autonom-
ic nervous systems.8 In addition, NCS shows mildly slow 
nerve conduction velocity and low amplitude in diabetic 
polyneuropathy, suggesting that the peripheral neuropathy 
of type 2 diabetes mellitus is primarily caused by axonal 
degeneration.9,10 
Because type 2 diabetes mellitus is a chronic disease, the 
management of complications such as neuropathy is impor-
tant in terms of quality of life. However, a diagnosis of dia-
betic neuropathy can be difficult to make, when  based only 
on clinical characteristics. Patients do not express symp-
toms in the course of mild neuropathy, and it is very diffi-
cult to identify subclinical diabetic neuropathy without per-
forming procedures such as NCS.11 Moreover, in the early 
stage of diabetic neuropathy, NCS can only detect the most 
distal sensory nerves, such as medial-plantar and dorsal su-
ral nerves, which are not usually included in routine nerve 
conduction studies.12
The purpose of this study is to determine whether insulin 
resistance is associated with the development and progres-
sion of neuropathy in patients with type 2 diabetes mellitus. 
We previously demonstrated that insulin resistance is inde-
pendently associated with peripheral neuropathy in Korean 
patients with type 2 diabetes mellitus.4 In this study, we an-
alysed the follow-up results of blood tests and electrophysi-
Fig. 1. Enrollment and follow-up of the study patients. DMPN, diabetes mel-
litus induced polyneuropathy; NCS, nerve conduction study; NCV, nerve 
conduction velocity.
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considered affected by neuropathy.11 In the absence of a re-
sponse, the contralateral nerve was assessed.14
Insulin resistance
Serum insulin resistance was measured using a short insu-
lin tolerance test and estimated by the Kitt index as previ-
ously described.15 On the morning of the test day after more 
than 10 h of fasting, a 20-gauge catheter was inserted into 
one arm, a 3-way tap was connected, and blood was ob-
tained. A second 20-gauge catheter was inserted for insulin 
and glucose infusion. After insertion of the second catheter, 
patients were allowed to rest in the supine position for 20-
30 min. A 1:100 dilution of insulin (insulin lispro, 0.1 u/kg) 
was then injected. Blood was obtained through the 3-way 
tap just prior to injection (0 min) and at 3, 6, 9, 12, and 15 
min after injection and was stored in a tube with ethylene-
diaminetetraacetic acid. Serum glucose was measured, and 
the Kitt value was obtained by linear regression analysis of 
the decrease in the log glucose value between 3 and 15 min 
as follows: 
Kitt (rate constant for plasma glucose disappearance)= 
0.693/t1/2,
where t1/2 is the time at which the baseline blood glucose 
level reached 50% of its initial value.
Peripheral blood markers
All blood sampling was performed in the early morning af-
ter fasting since midnight. Plasma glucose was measured 
by the glucose oxidase technique using an auto-analyser 
(Beckman, Fullerton, CA, USA). HbA1c was analysed us-
ing high-performance liquid chromatography (Variant II, 
Bio-Rad, Hercules, CA, USA). Insulin and C-peptides (fast-
ing and postprandial) were measured using radioimmunoas-
say (Instar, Stillwater, MN, USA). 
 The glycaemic exposure (GE) Index was calculated us-
ing the following equation:16
GE Index=(HbA1c)1/2×(duration of DM in years)1/8 
Statistical analysis
Continuous variables are given as means with standard de-
viation, and categorical variables are given as frequencies 
and percentages. Univariate analysis was initially performed 
to evaluate potential covariates associated with the develop-
ment of neuropathy. Multivariate analysis using binary lo-
dorsalis pedis arterial pulsation, and previous history of neu-
rologic disorders including stroke, peripheral vascular oc-
clusive disease, autoimmune disease, or any other possible 
causes of peripheral neuropathy. 
This study was approved by the human research ethical 
committee at Yonsei University College of Medicine, Seoul, 
Korea (No.3-2013-0006).
Analytical methods
All patients had height and weight measured for body mass 
index (BMI) determination, and the following tests were 
performed upon enrolment in the study.
Diagnosis of peripheral neuropathy
The diagnosis of peripheral neuropathy was made in two 
stages: objective neurologic exams and electrophysiologic 
studies, with slight modifications from the Michigan Dia-
betic Neuropathy Score.11,14
For neurologic examinations, each patient was assessed 
for sensitivity, muscle strength, and reflexes of the bilateral 
upper and lower extremities and scored accordingly.11 Vi-
bratory sensitivity was evaluated using a 128-Hz tuning 
fork and touch sensitivity with a 10 g monofilament. Mus-
cle strength was assessed by abduction of the fingers, ex-
tension of the great toe, and the ankle dorsiflexion. In addi-
tion, reflexes of upper and lower limbs were evaluated.
NCS were performed using electromyography (Key-
point, Dantec Medical, Skovlunde, Denmark). Skin tem-
perature was measured at the forearm and was maintained at 
>32°C. Motor and sensory nerve conduction velocities were 
measured in median, ulnar, peroneal, posterior tibial, and su-
ral nerves using standard methods. Electrical stimuli were 
produced at supramaximal intensity. Sensory nerve conduc-
tion was measured using a 0.2-ms duration square wave 
pulse, 20-2000 Hz filter, 1 ms/division sweep speed, and 10 
µV/ division sensitivity. Motor nerve conduction studies were 
performed using 2-10000 Hz filter, 2 ms/division sweep 
speed, and 2 mV/division sensitivity. NCS values lower than 
the 95th percentile of the normal control values were con-
sidered abnormal.
The diagnosis of peripheral neuropathy was made when 
the clinical score was greater than 6 and/or in the presence 
of at least two abnormal results in NCS, amplitudes, or 
peak latencies.11,14 A reduction in motor or sensory NCS in 
two or more nerves independent of the clinical scores was 
considered sufficient for diagnosis, whereas patients with 
only one abnormal nerve conduction parameter were not 
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were normal in both 2006 and 2012, and 6 patients who 
had normal results in 2006 were diagnosed with peripheral 
neuropathy in 2012. The remaining 9 patients had peripher-
al neuropathy already in 2006. The clinical characteristics 
of the patients are presented in Table 1.
In univariate logistic regression analysis, higher BMI, low-
er high-density lipoprotein (HDL) cholesterol, and higher 
triglyceride levels were related to the presence of peripheral 
neuropathy (Table 2). However, gender, age, C-peptide, in-
sulin, HbA1c, cholesterol, DM duration, GE Index and 
number of abnormal autonomic function test were not cor-
related with peripheral neuropathy. In multivariate analysis 
using binary logistic regression, high triglyceride and low 
HDL cholesterol were significantly associated with periph-
eral neuropathy after adjusting for age and gender (Table 3). 
As in 2006, lower HDL cholesterol in 2012 increased the 
odds ratio for peripheral neuropathy. 
We selected patients with a mean HbA1c <7% and good 
blood glucose control from 2006 to 2012. Among these pa-
tients, a lower Kitt value in 2006 was related to the occur-
rence of peripheral neuropathy in 2012 (Table 4). 
The patients were divided into three groups according to 
the follow-up NCS results in 2012. In group I patients (n=33), 
gistic regression was then used for determination of inde-
pendent predictors of the presence of peripheral neuropathy. 
A p-value less than 0.05 was considered statistically signifi-
cant. A general linear model was used to analyse the vari-
ability of NCS data between 2006 and 2012. The Kruskal-
Wallis test was used as a non-parametric test for comparisons 
between the three groups that were classified by the results 
of NCS.
Statistical analysis was performed using SPSS version 
18.0 (Statistical Package for Social Sciences, SPSS Inc., 
Chicago, IL, USA).
RESULTS
 
Among 86 patients, 40 (46.5%) were diagnosed with pe-
ripheral neuropathy in 2006.4 According to the results of our 
2006 study, insulin resistance (1/Kitt value), GE Index, du-
ration of diabetes mellitus, and HDL cholesterol level were 
significantly different between the peripheral neuropathy 
group and non-neuropathy group. In 2012, we repeated NCS 
and blood sampling in 48 of the original 86 patients. In 33 
patients, the results of NCS and neurologic examination 
Table 1. Patient Demographics and Characteristics
Variables
2006 (n=86) 2012 (n=48)
Normal NCS 
(n=46)
Abnormal NCS 
(n=40)
Total (n=86)
Normal NCS 
(n=33)
Abnormal NCS 
(n=15)
Total (n=48)
Age (yrs)    54.26±10.55  55.93±9.23 55.10±9.89 63.15±8.81  66.60±5.47 64.88±7.14
Male-Female ratio 3 5.67 4.25 2.18 6.5 4.34
Duration (yrs)    2.84±2.86    7.69±6.94 5.27±4.9 14.12±8.39  15.73±5.43 14.93±6.91
BMI (kg/m2)  23.86±3.17  24.87±2.76 24.37±2.97 24.09±3.34  25.74±2.66 24.92±3.00
C-peptide (nmol/L)    1.90±0.82    2.19±0.71   2.05±0.77   7.44±3.49    3.96±1.55   5.70±2.52
Insulin (pmol/L)    7.96±4.50    9.54±9.03   8.75±6.77   8.21±3.82    3.75±2.00   5.98±2.91
HbA1c (%)    7.30±1.73    8.20±1.71   7.75±1.72   7.02±0.84    8.34±5.48   7.68±3.16
Triglyceride (mg/dL)  162.83±51.21  176.70±45.48 169.77±48.35 136.24±51.29  169.27±42.48 152.76±46.89
Cholesterol (mg/dL)  182.80±35.38  180.00±30.55   181.4±32.97 178.33±20.80  185.27±18.46   181.8±19.63
LDL-cholesterol (mg/dL)    97.96±36.64    99.86±32.33   98.91±34.49 104.93±16.39  115.29±14.75 110.11±15.57
HDL-cholesterol (mg/dL)    52.28±12.76  44.80±8.43   48.54±10.60   50.03±10.70    40.93±12.87   45.48±11.79
GE Index    1.33±1.47    4.24±4.59   2.79±3.03   6.15±3.97    6.38±3.40   6.27±3.69
Kitt value in 2006 (%/min)    2.81±0.89    2.39±0.94     2.6±0.92     2.69±0.68*      1.93±0.54*     2.31±0.61*
MDNS    0.54±1.31    2.18±2.22   1.36±1.77   1.15±1.00    6.33±1.50   3.74±1.25
Number of abnormal 
  autonomic function test
   2.33±0.47    2.93±0.27   2.63±0.37   2.09±0.68    2.00±0.76   2.05±0.72
Abnormal NCS_Segment    0.20±0.40    5.43±2.58   2.82±1.49   0.36±0.49    8.47±3.64   4.42±2.07
BMI, body mass index; GE Index, glycemic exposure index; MDNS, Michigan Diabetic Neuropathy Score; NCS, nerve conduction study; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein.
Kitt values=1/insulin resistance.
*This value was calculated in 2006.
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Table 2. Univariate Analysis of Risk Factors for the Development of Peripheral Neuropathy after 6 Years Follow-Up
Variables
Peripheral neuropathy
Odds ratio 95% CI p value
Gender
    Male 1
    Female 0.41   0.77-2.189 0.462
Age (yrs)
    <60 1
    60-70 3.692   0.650-20.969 0.252
    >70 3.75   0.579-24.282 0.209
C-peptide (nmol/L)
    <3.2 1
    >3.2 0.28 0.077-1.017 0.096
Insulin (pmol/L)
    <10 1
    >10 0.559 0.146-2.138 0.521
HbA1c (%)
    <6 1
    6-8 0.448 0.026-7.734 0.540
    >8 0.333   0.009-11.939 1
BMI (kg/m2)
    <25 1
    >25 4.6   1.247-16.967 0.018
Cholesterol (mg/dL)
    <200 1
    >200 2.5   0.441-14.168 0.360
HDL-C (mg/dL)
    <45 1
    >45 0.25 0.068-0.912 0.031
Triglyceride (mg/dL)
    <177 1
    >177 6.325   1.617-24.745 0.011
DM duration (yrs)
    <10 1
    10-20 3.111   0.774-12.508 0.161
    >20 3   0.501-17.954 0.327
GE Index
    0-3.0 1
    3.0-4.0 0.409 0.045-3.684 0.570
    >4.0 0.789 0.113-5.528 0.590
Kitt value
    >2.7 1
    2.0-2.7 6.333   0.920-43.618 0.067
    0.0-2.0 10.688   1.875-60.931 0.005
Number of abnormal AFT
    1-2 1
    3-5 1.222 0.672-1.892 0.312
AFT, autonomic function test; BMI, body mass Index; GE Index, glycemic exposure index; HDL-C, high-density lipoprotein cholesterol; DM, diabetes mel-
litus; CI, confidence interval.
Fisher’s exact test was used for cells with the expected count less than 5. Kitt values=1/insulin resistance.
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and height (Fig. 3). 
DISCUSSION
In addition to clearly symptomatic diabetic neuropathy pa-
tients, asymptomatic patients also often undergo mild neu-
NCS results were normal in 2006 and 2012. In group II pa-
tients (n=6), NCS results were normal in 2006, but abnor-
mal at the follow-up NCS in 2012. Group III patients (n=9) 
had already been diagnosed with diabetic neuropathy by 
NCS in 2006. 
The Kitt value reflects insulin resistance: the lower the Kitt 
value, the higher the insulin resistance. The Kitt value of 
these three groups was significantly different (Kruskal-Wal-
lis test, p=0.004). In post-hoc analysis, a significant differ-
ence in Kitt value was observed between groups I and II 
(Dunn’s procedure, p=0.046) and between groups I and III 
(Dunn’s procedure, p=0.025). There was no significant dif-
ference in Kitt value between groups II and III (Fig. 2).
We compared the follow-up NCS results and the data 
from 2006 for each group. In group I, there was no differ-
ence between the 2006 and 2012 results. In groups II and 
III, sural sensory nerve conduction velocity and sensory 
nerve action potential (SNAP) amplitude were reduced in 
2012 compared with the 2006 results, but there were no 
significant differences in the other parameters of NCS, such 
as median, ulnar, and tibial nerve conduction. 
Insulin resistance in 2006 showed a positive correlation 
(r=0.629, p=0.001) with differences in sural SNAP in group 
III between 2006 and 2012 after adjusting for age, gender, 
Table 3. Multivariate Analysis Using Binary Logistic Regression of Risk Factors for Peripheral Neuropathy after 6 Years (Ad-
justed for Age and Gender)
Variables
Logistic regression
Odds ratio 95% CI p value
BMI (kg/m2)
    <25 1
    >25 2.558 0.456-14.340 0.285
HDL-C (mg/dL)
    >45 1
    <45 5.292 1.001-27.989 0.050
Triglyceride (mg/dL)
    <177 1
    >177 6.129 1.057-35.528 0.043
BMI, body mass index; HDL-C, high-density lipoprotein cholesterol; CI, confidence interval.
Table 4. The Relationship between Initial Insulin Resistance and Peripheral Neuropathy in Patients with HbA1c <7% during 6 
Years
Variables
Logistic regression
Odds ratio 95% CI p value
Kitt value
    >2.7 1
    2.0-2.7   4.000   0.424-37.778 0.226
    0.0-2.0 11.200 1.735-2.300 0.011
CI, confidence interval.
Kitt value=(1/insulin resistance).
Fig. 2. A significant difference in Kitt value was observed between groups I 
and II, and between groups I and III. Kitt values=1/insulin resistance.
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apeutic target in type 2 diabetes mellitus.22,23 
HbA1c values reflect overall glycaemic exposure over the 
prior 2-3 months.24,25 The American Diabetes Association 
-recommended treatment goal to prevent microvascular 
complications in type 2 diabetes mellitus patients is HbA1c 
<7%, which is considered the standard for the monitoring 
of glycaemic control.26,27 Recent studies have shown that 
high HbA1c is correlated with subclinical diabetic neuropa-
thy.28 However, these studies are likely limited, because the 
authors did not control the effects of other risk factors such 
as obesity or dyslipidaemia. Obesity, dyslipidaemia, and im-
paired insulin tolerance are components of metabolic syn-
drome that may potentially influence the occurrence of idio-
pathic neuropathy.29 Therefore, without controlling metabolic 
risk factors, it may be incorrect to conclude that only glycae-
mic control affects the development of diabetic neuropathy.
In this study, multivariate analysis showed that patient gen-
der, age, and obesity were not independent risk factors for di-
abetic neuropathy. However, as in our previous study, low 
HDL cholesterol showed a strong association with neuropa-
thy, indicateing that the management of dyslipidaemia in pa-
tients with type 2 diabetes mellitus is important for the pre-
vention of neuropathy. Microvascular events caused by 
dyslipidaemia seem to have a lasting impact, even after sever-
al years. However, there was no relationship between dyslipi-
daemia and neuropathy in patients with HbA1c levels <7%.
Our study showed no difference in insulin resistance be-
tween groups II and III; however, there were significant dif-
ferences when comparing groups I and II as well as groups 
I and III. This indicates that past insulin resistance contrib-
utes to the expression of neuropathy after many years. In 
particular, we found a relationship between low Kitt value 
in the past and worsened NCS data in the current study, even 
in patients with good glycaemic control and mean HbA1c 
<7% over the past 6 years. Therefore, past insulin resis-
tance affects the onset of neuropathy many years later, even 
if glycaemic control is well managed.
The group III patients already had neuropathy in the previ-
ous study. We found that the changes in SNAP in this group 
between 2006 and 2012 showed a positive correlation with 
past insulin resistance after adjusting for age and height. 
Higher insulin resistance in the past can therefore accelerate 
the deterioration associated with the process of neuropathy in 
type 2 diabetes mellitus. A decrease in SNAP, compared with 
past NCS data indicates the progression of neuropathy, even 
in mildly symptomatic or asymptomatic patients.  
The current study has several limitations. First, as in our 
ropathic changes.17 Follow-up NCS should therefore be 
considered in patients with diabetes mellitus in the absence 
of overt symptoms of neuropathy.11 Such studies also allow 
physicians to determine the extent of deterioration due to 
diabetic neuropathy in patients with very mild symptoms. 
In this study, we investigated the risk factors for the devel-
opment of diabetic neuropathy in type 2 diabetes mellitus 
over a 6-year follow-up period. Our earlier findings showed 
that insulin resistance and lower HDL cholesterol are asso-
ciated with diabetic neuropathy. Here, we investigated the 
relationship between insulin resistance in the past and the 
later occurrence of neuropathy. 
Over the past decade, mitochondrial dysfunction has been 
shown to play a key role in the pathologic features of insulin 
resistance.18 Mitochondrial fission in both cell bodies and 
neurites increase during hyperglycaemic injury in dorsal root 
ganglia and axons.19 Excessive mitochondrial fission may re-
sult in dysregulation of energy production, activation of cas-
pase-3, and subsequent dorsal root ganglion neuron inju-
ry.19,20 Similar to other peripheral tissues, the expression of 
the insulin receptor protein on ganglion cells is altered by hy-
perglycaemia and consequent activation of downstream insu-
lin receptor signalling contributes to the onset of diabetic 
neuropathy in animal models.20 In addition, hyperlipidaemia 
causes an increase in oxidized lipoproteins, and lipoprotein 
receptors on the dorsal root ganglia cause oxidative stress, 
which induces neuropathy.21 Several studies have provided 
strong evidence that dyslipidaemia contributes to macro and 
microvascular complications, and lipid control is a new ther-
Fig. 3. Insulin resistance in 2006 showed a positive correlation (r=0.629, 
p=0.001) with changes in sural SNAP in group III between 2006 and 2012. r, 
Pearson’s correlation coefficient; SNAP, sensory nerve action potential.
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tes Care 2006;29:2282-8.
17. Albers JW, Herman WH, Pop-Busui R, Martin CL, Cleary P, 
Waberski B, et al. Subclinical neuropathy among Diabetes Control 
and Complications Trial participants without diagnosable neurop-
athy at trial completion: possible predictors of incident neuropa-
thy? Diabetes Care 2007;30:2613-8.
18. Turner N, Heilbronn LK. Is mitochondrial dysfunction a cause of 
insulin resistance? Trends Endocrinol Metab 2008;19:324-30. 
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peutics 2012;9:262-9. 
21. Vincent AM, Hayes JM, McLean LL, Vivekanandan-Giri A, Pen-
nathur S, Feldman EL. Dyslipidemia-induced neuropathy in mice: 
previous study, this study was conducted only on patients 
with type 2 diabetes mellitus. Comparison of our results 
with data for a normal control group would provide more 
comprehensive results. Second, the gender distribution of 
our data was not even, and there were many more males 
than females. Many reports have shown that males are more 
vulnerable to neuropathy than females;30,31 therefore, this 
gender bias should be considered when interpreting the re-
sults. Third, the Kitt value reflects insulin resistance, as as-
sessed by a short insulin tolerance test instead of the eugly-
caemic hyperinsulinaemic clamp test. In addition, we could 
not test the Kitt value in this follow-up study. Insulin toler-
ance test must be performed in monitoring room because of 
unexpected low glucose level. Thus, Kitt value is not neces-
sary test for common follow-up patients. We designed this 
study retrospectively, so that the Kitt value is not checked 
again. Nevertheless, the values of repeated measurements 
of insulin intolerance test may allow us to explain the rela-
tionship between insulin resistance and diabetic neuropathy. 
Fourth, small number of patients could not show powerful 
results in statistical analysis. We added dunn’s procedure to 
calibrate the results of Kruskal-Wallis test.
In conclusion, insulin resistance seems to be associated 
with peripheral neuropathy, independent of blood glucose 
level, in Korean patients with type 2 diabetes mellitus, and 
diabetic neuropathy can be affected by previous insulin re-
sistance in spite of regular glycaemic control. In addition, 
dyslipidaemia should be controlled in patients who have 
shown high insulin resistance in the past, because HDL cho-
lesterol and triglyceride levels are strongly correlated with 
diabetic neuropathy. Physicians should consider regular fol-
low-up electrophysiologic tests in patients with type 2 dia-
betes mellitus who have no neuropathic symptoms, even if 
they are normal on NCS. 
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